Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Reexamination Certificate
2002-12-26
2008-12-02
Schnizer, Richard (Department: 1635)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
C424S204100, C424S205100, C424S233100, C435S235100, C435S456000, C514S040000
Reexamination Certificate
active
07459154
ABSTRACT:
Agents and methods for enhancing recombinant virus transduction in the bladder epithelium are described. A first method involves contacting the luminal surface of the bladder with a composition comprising a transduction enhancing agent and an oncolytic virus. Alternatively, the luminal surface of the bladder can be contacted first with a pretreatment composition comprising a transduction enhancing agent and, subsequently, with a composition comprising an oncolytic virus. Bladder treatment compositions comprising a transduction enhancing agent and an oncolytic virus are also described.
REFERENCES:
patent: 5368844 (1994-11-01), Gaffar et al.
patent: 5369095 (1994-11-01), Kee et al.
patent: 5789244 (1998-08-01), Heidrun et al.
patent: 6008177 (1999-12-01), Sata et al.
patent: 6165779 (2000-12-01), Engler et al.
patent: 2002/0120117 (2002-08-01), Yu et al.
patent: 2002/0169138 (2002-11-01), Kunz et al.
patent: 2003/0068307 (2003-04-01), Yu et al.
patent: 01245159 (1989-09-01), None
patent: WO 02/40630 (2002-05-01), None
CAPLUS Accession No. 1990:115384, 1990.
Zhang et al (Cancer Res. 62: 3743-3750, 2002).
Connor et al (Gene Therapy 8: 41-48, 2001).
Watanabe et al (Int. J. Cancer 92: 712-717, 2001).
Mullen et al (Oncologist 7:106-119, 2002).
Boer et al (Biochem. Biophys Res. Comm. 166(1): 91-98, 1983).
Sedzik et al (NeuroReport 11(11): 2559-2563, 2000).
Kim (Oncogene 19: 6660-6669, 2000).
Rangel (Cancer Chemo. Pharm. 33(6): 460-464, 1994).
Loughlin et al (J. Urol. 165: 1300-1304, 2001).
http://www.biomol.de/dateien/infos—nr45.pdf, retrieved from the internet on Aug. 10, 2005.
Sutton et al (Mol. Ther. 2(3): 211-217, 2000).
Cozzi et al (FASEB J. (Mar. 5, 2001) 10.1096/fj.00-0533fje).
Translation of Mizamura et al (JP 01245159, Sep. 29, 1989).
Dumont et al (Oncogene 18: 747-757, 1999).
Siemens et al., “Evaluation of Gene Transfer Efficiency by Viral Vectors To Murine Bladder Epithelium”, J. Urol., 165, 667-671, Feb. 2001.
Zhang et al., “Identification of Human Uroplakin II Promoter and Its Use in the Construction of CG8840, a Urothelium-specific Adenovirus Variant That Elimanates Established Bladder Tumors in Combination with Docetaxel”, Cancer Research, 62, 3743-3750, Jul. 1, 2002.
Raghavan et al., “Biology and Management of Bladder Cancer”, N. Engl. J. Med., 322, 16, 1129-1138, Apr. 19, 1990.
Brewster et al., “Gene Therapy in Urological Oncology: Principles, Strategies and Potential”, Eur. Urol., 25, 177-182, 1994.
Takahashi et al., “The Retinoblastoma Gene Functions As A Growth And Tumor Suppressor In Human Bladder Carcinoma Cells”, Proc. Natl. Acad. Sci. USA, 88, 5257-5261, Jun. 1991.
Rosenberg, “The Immunotherapy and Gene Therapy of Cancer”, J. Clin. Oncol., 10, 2, 180-199, Feb. 1992.
Bass et al., “Recombinant Adenovirus-Medicated Gene Transfer To Genitourinary Epithelium In Vitro and In Vivo”, Cancer Gene Therapy, 2, 2, 97-104, 1995.
Morris, Jr. et al., “Adenoviral-Medicated Gene Transfer To Bladder In Vivo”, J. of Urol. 152, 506-509, Aug. 1994.
Blixt et al, “Enhancement Of Intracellular Uncoating Of Adenovirus In HeLa Cells In The Presence of Benzyl Alcohol As a Membrane Fluidizer”, Arch. of Virol., 129, 265-277, 1993.
Monson, et al., “Indigocarmine As A Quantitative Indicator Of Urothelial Integrity”, J. of Urol., 145, 842-845, Apr. 1991.
Parson et al., “Bladder Surface Glycosaminoglycans: An Epithelial Permeability Barrier”, J. of Urol., 143, 139-142, Jan. 1990.
Good et al., “Hydrogen Ion Buffers For Biological Research”, Biochemistry, 5, 467-477, Feb. 1966.
Broad Spectrum Antimicrobial For Topical Clorpactin WCS-90, Aug. 2000.
Boer et al., 1983, Solubilization of Ligand-Stabilized Vasopressin Receptors from Plasma Membranes of Bovine Kidney and Rat Liver, Biochem. Biophys. Res. Comm., 116(1):91-98.
Kirn, 2000. Replication-selective oncolytic adenoviruses:virotherapy aimed at genetic targets in cancer, Oncogene 19:6660-6669.
Mullen et al., 2002, Viral Oncolysis, The Oncologist 7:106-119.
Sedzik et al., 2002, Solubilization of PNS myelin membrane proteins by detergents, Membrane Biophysics and Biochemistry 11(11)2559-2563.
Frey David
Memarzadeh Bahram
Ramesh Nagarajan
Yu De-Chao
Cell Genesys Inc.
Chen Teresa A.
Haley Jr. James F.
Ropes & Gray LLP
Schnizer Richard
LandOfFree
Methods and reagents for the enhancement of virus... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and reagents for the enhancement of virus..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and reagents for the enhancement of virus... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4023556